Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
96.14
-0.08 (-0.08%)
Dec 5, 2025, 4:00 PM EST - Market closed
Merus Employees
As of December 31, 2024, Merus had 321 total employees, including 260 full-time and 61 part-time employees. The number of employees increased by 92 or 40.17% compared to the previous year.
Employees
321
Change (1Y)
92
Growth (1Y)
40.17%
Revenue / Employee
$176,343
Profits / Employee
-$1,187,336
Market Cap
7.29B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MRUS News
- 11 days ago - Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout - Seeking Alpha
- 19 days ago - Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - PRNewsWire
- 5 weeks ago - 3 Investable Laggards In An Overbought Market - Seeking Alpha
- 6 weeks ago - Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety - GlobeNewsWire
- 6 weeks ago - Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 6 weeks ago - Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. - GlobeNewsWire
- 7 weeks ago - Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 7 weeks ago - Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire